NCT03359213已完成2 期
Phase II Study of JR-141 in Patients With Mucopolysaccharidosis II
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Number of participants with Adverse Events
研究概览
简要总结
A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the safety and efficacy of 3 doses of study drug for the treatment of the MPS II.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males with confirmed diagnosis of MPS II, based on deficient activity of IDS in leucocytes or fibroblasts and/or pathogenic mutations identified in the IDS gene (if enzyme diagnosis was in dried blood spots or plasma, molecular genetics confirmation is mandatory).
- •One of the following age groups:
- •0 to 3 years and 11 months old (6 patients, 2 in each dose)
- •4 years to 7 years and 11 months old (6 patients, 2 in each dose)
- •8 years or older (6 patients, 2 in each dose)
- •Capable of providing written consent by himself, unless the patient is under the age of 18 years at the time of informed consent process, or it is not possible to obtain consent from the patient himself due to his intellectual disabilities associated with MPS II.
- •In the case of a patient who is under the age of 18 years or from whom it is not possible to obtain consent due to his intellectual disabilities associated with MSP II, he may be included if written consent can be provided by legal representative; however written consent should be obtained from the patient himself too, wherever possible.
- •Naïve patients or patients who are receiving enzyme replacement therapy with idursulfase could be included if provided treatment has been stable in the last 6 months and agree to interrupt the treatment at least one week before the first study drug infusion, and agree in suspending this treatment for the duration of the trial.
排除标准
- •Refusal to sign the informed consent form.
- •Unable to perform the study procedures, except for neurocognitive testing.
- •Previous engrafted BMT/HSCT.
- •Surgical or other major medical intervention planned to occur before week
- •Participation in a clinical trial with an investigational drug in the last 12 months.
- •Judged by the investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking a position for lumber puncture due to joint contracture or those who are likely to experience difficulty breathing during the lumbar puncture process.
- •Judged by the investigator or subinvestigator to be ineligible to participate in the study due to a history of a serious drug allergy or sensitivity.
- •Otherwise judged by the investigator or subinvestigator to be ineligible to participate in the study out of consideration for the subject safety.
研究组 & 干预措施
JR-141 1.0 mg/kg/week
Experimental
干预措施: JR-141 (Drug)
JR-141 2.0 mg/kg/week
Experimental
干预措施: JR-141 (Drug)
JR-141 4.0 mg/kg/week
Experimental
干预措施: JR-141 (Drug)
结局指标
主要结局
Number of participants with Adverse Events
时间窗: 26 weeks
* Adverse events * Antidrug antibodies * Blood pressures in mmHg * Heart rate in beats/minute * Respiratory rate in breaths/minute * Temperature in °C * Presence or absence of abnormalities for physical examination * Presence or absence of abnormalities for 12-lead electrocardiogram * Routine laboratory tests in blood (hematology, liver function, renal function, iron-related levels) and urine (urinalysis)
次要结局
- Plasma Pharmacokinetic parameter [Maximum Plasma Concentration [Cmax]](21 hours after dosing at the first and last infusions)
- Left ventricular mass by a standard 2-dimensional Doppler echocardiogram(26 weeks)
- Urinary dermatan sulfate concentrations(26 weeks)
- Serum heparan sulfate concentrations(26 weeks)
- Plasma Pharmacokinetic parameter [Area Under the Curve [AUC]](21 hours after dosing at the first and last infusions)
- Liver and spleen volumes (MRI)(26 weeks)
- Serum dermatan sulfate concentrations(26 weeks)
- Urinary heparan sulfate concentrations(26 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of JR-171 in Patients With Mucopolysaccharidosis IMucopolysaccharidosis INCT04227600JCR Pharmaceuticals Co., Ltd.18
已完成
1 期
A Study of JR-141 in Patients With Mucopolysaccharidosis Type IIMucopolysaccharidosis IINCT03128593JCR Pharmaceuticals Co., Ltd.14
进行中（未招募）
3 期
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)Mucopolysaccharidosis IINCT04573023JCR Pharmaceuticals Co., Ltd.86
已完成
2 期
A Study of JR-141 in Patients With Mucopolysaccharidosis IIMucopolysaccharidosis IINCT03568175JCR Pharmaceuticals Co., Ltd.28
进行中（未招募）
2 期
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type IIMucopolysaccharidosis IINCT04348136JCR Pharmaceuticals Co., Ltd.27